newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Devdiscourse
Roche CEO Thomas Schinecker cites 'mind-blowing' bureaucracy as a major hurdle.
Roche CEO Thomas Schinecker warns Europe's pharma sector risks falling behind the U.S. and China.
KEY POINTS
Schinecker identifies excessive bureaucracy in Europe as a significant barrier for pharmaceutical innovation.
U.S. policy tying drug prices to cheaper foreign alternatives impacts European drug launch strategies.
Roche and Sanofi remain committed to European markets, actively negotiating pricing amid regulatory challenges.
Europe's pharmaceutical industry is under strain as it risks trailing the U.S. and China, warned Roche CEO Thomas Schinecker, citing 'mind-blowing' bureaucracy as a major hurdle.
This warning follows U.S. President Trump's policy linking American drug prices to cheaper alternatives abroad, significantly affecting European launches.
Despite acknowledging the challenges, industry leaders from Roche and Sanofi emphasize their commitment to introducing new drugs in Europe, negotiating pricing strategies to sustain innovation and market access.
(With inputs from agencies.)